enVVeno Medical Advances FDA Pivotal Trial for enVVe System
IRVINE, Calif., July 31, 2026 enVVeno Medical Corporation reported its second quarter 2026 financial results, highlighting significant progress toward...
clinical trial
Advertisement
Leads Biolabs Completes Opamtistomig Phase II Enrollment in BTC
NANJING, China, July 30, 2026 Leads Biolabs announced that its Phase II clinical trial evaluating Opamtistomig (LBL-024), a proprietary...
Trace Biosciences and Axogen Advance Nerve Trace Technology
PORTLAND, Ore., July 29, 2026 Trace Biosciences, Inc. has secured a strategic investment from Axogen, Inc. to accelerate clinical...
Replimune’s RP1 Gains FDA Panel Support for Advanced Melanoma
WOBURN, Mass., July 30, 2026 Replimune Group, Inc. announced a favorable outcome from the U.S. Food and Drug Administration’s...
Hansoh Pharma’s Ris-Rez Succeeds in Phase 3 Osteosarcoma Trial
SHANGHAI, July 28, 2026 Hansoh Pharmaceutical Group Co., Ltd. announced that risvutatug rezetecan (Ris-Rez/HS-20093), its proprietary B7-H3-directed antibody-drug conjugate...
Advertisements
FibroBiologics Advances CYWC628 Phase 1/2 Wound Trial
HOUSTON, July 31, 2026 FibroBiologics, Inc. has begun dosing patients in its Phase 1/2 clinical trial evaluating CYWC628, a...
Johnson & Johnson Advances RYBREVANT for Head and Neck Cancer
RARITAN, N.J., July 30, 2026 Johnson & Johnson has secured U.S. Food and Drug Administration Priority Review for a...
Nitinotes Advances EndoZip With First Orlando Health Procedures
CAESAREA, Israel, July 28, 2026 Nitinotes Ltd. has completed the first study procedures at Orlando Health in its pivotal...
Contineum Therapeutics Affirms Phase 2 Milestones and Cash Runway
SAN DIEGO, July 30, 2026 Contineum Therapeutics, Inc. reported its second-quarter 2026 financial results while reaffirming key clinical development...
Moleculin Reports Positive Interim MIRACLE Trial Data in Venetoclax-Failed AML Patients
HOUSTON, July 31, 2026 Moleculin Biotech, Inc. announced updated positive preliminary blinded interim results from Part A of its...
Advertisement
